{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006319","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.119988+00:00","generated_at":"2026-06-03T03:38:40.108826+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bio-Techne Q3 FY2024: Revenue $303.4M (+2% organic); GAAP EPS $0.31 vs $0.43; declares $0.08 dividend","bullets":["Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.","Diagnostics & Genomics segment organic growth 10% (reported 16%); record GMP reagent sales in cell/gene therapy.","Cash from operations $223.5M, up 31% YoY.","Quarterly dividend of $0.08 per share, payable May 24, 2024; record date May 13, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006319","json":"https://secwatch.observer/filing/0001558370-24-006319.json","markdown":"https://secwatch.observer/filing/0001558370-24-006319.md","text":"https://secwatch.observer/filing/0001558370-24-006319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837024006319/0001558370-24-006319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837024006319/tmb-20240501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:38:40.108826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"670a2189ee5de586dd0679d527fff099fd3248aa","claim":"BIO-TECHNE Corp reported the third quarter ending March 31, 2024 results: revenue $303.4 million, EPS $0.31.","evidence_excerpt":"reported its financial results for the third quarter ending March 31, 2024. ​ Third Quarter FY2024 Highlights ​ ● Third quarter organic revenue increased by 2% (3% reported) to $303.4 million. ​ ● GAAP earnings per share (EPS) was $0.31 versus $0.43 one year ago. Delivered adjusted EPS of $0.48 compared to $0.53 one year ago. ​ ● Strong commercial execution in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837024006319/0001558370-24-006319-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ending March 31, 2024"},{"label":"Revenue","value":"$303.4 million"},{"label":"EPS","value":"$0.31"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}